Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Other · 2026

Orzeyful (oveporexton)

The FDA approved Orzeyful (oveporexton) on August 5, 2026 to treat narcolepsy type 1.
Brand name
Orzeyful
Generic name
oveporexton
FDA approval date
August 5, 2026
Approved use (FDA wording)
To treat narcolepsy type 1
Category on this site
Other

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.